DDInter1101 DDInter1658
Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lum
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Lumacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enfortumab vedotin
Lumacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Meloxicam
Lumacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enasidenib
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Tolvaptan
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Capmatinib
Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Lumacaftor may lead to a major life threatening interaction when taken with Tolvaptan
Lumacaftor may lead to a major life threatening interaction when taken with Capmatinib